NeuroSense Therapeutics Ltd. Ordinary Shares
NRSN
NRSN: NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
moreShow NRSN Financials
Recent trades of NRSN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by NRSN's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases Apr. 20, 2021
Federal grants, loans, and purchases
Followers on NRSN's company Twitter account
Number of mentions of NRSN in WallStreetBets Daily Discussion
Recent insights relating to NRSN
Recent picks made for NRSN stock on CNBC
ETFs with the largest estimated holdings in NRSN
Flights by private jets registered to NRSN